Phase 1 study of BLU-285 in patients with advanced systemic mastocytosis
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs BLU 285 (Primary)
- Indications Systemic mastocytosis
- Focus Adverse reactions
- Sponsors Blueprint Medicines
- 02 Aug 2017 Blueprint Medicines completed enrollment in the dose escalation portion and began enrolling patients in the dose expansion portion of this clinical trial at the recommended dose of 300 mg once daily, as reported in a media release. The company anticipates providing updated data from this clinical trial by the end of 2017.
- 28 Oct 2016 Preliminary data from the dose escalation portion of this Phase 1 clinical trial will be presented at the 2016 American Society of Hematology (ASH) Annual Meeting.
- 17 Mar 2016 New trial record